Drugs / Ipratropium bromide/albuterol
Ipratropium bromide/albuterol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01019694 | Nov 2009 → Apr 2011 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ipratropium bromide/albuterol | “Ipratropium bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to ipratropium bromide/albuterol metered-dose inhaler (CVT-MDI),...” PMID 23658479 ↗ Mar 2013 |
| Known as | CVT-MDI | “Ipratropium bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to ipratropium bromide/albuterol metered-dose inhaler (CVT-MDI),...” PMID 23658479 ↗ Mar 2013 |
| Known as | CVT-R | “Ipratropium bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to ipratropium bromide/albuterol metered-dose inhaler (CVT-MDI),...” PMID 23658479 ↗ Mar 2013 |
| Route | Inhaled | “Patients were randomized to receive: (1) CVT-R, one inhalation four times daily (QID); or (2) CVT-MDI, two inhalations QID; or (3) I + A two inhalations of each inhaler QID.” PMID 23658479 ↗ Mar 2013 |